Riitta N.
- Country
- Finland
- Department
- Department of pediatrics
Research Overview
- Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
- Phase 3 Study of Imatinib with Cytotoxic Chemotherapy in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Evaluation of Quizartinib in Combination with Chemotherapy for Pediatric FLT3-ITD Positive, NPM1 Wild-Type Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 155 of 256 partner sites.
Specializations
Pediatric Leukemia Research
This investigator specializes in treating acute lymphoblastic leukemia and acute myeloid leukemia in children and adolescents, with particular expertise in age-specific therapeutic approaches.
- Philadelphia chromosome-positive ALL management
- Infant-specific leukemia protocols
- Pediatric AML treatment strategies
The research encompasses comprehensive treatment protocols for patients aged 0-18 years.
Advanced Treatment Protocols
The investigator focuses on developing and implementing innovative therapeutic strategies for various forms of leukemia, including targeted approaches for specific genetic markers.
- Risk-stratified treatment approaches
- Novel immunotherapy applications
- Chemotherapy optimization studies
Treatment protocols are designed to enhance survival rates while considering patient-specific factors.
Clinical Outcomes Research
The investigator's work centers on evaluating and improving disease-free survival and treatment efficacy across different leukemia subtypes.
- Long-term survival assessment
- Treatment response monitoring
- Quality of survival studies
Research efforts focus on enhancing treatment outcomes through systematic evaluation of therapeutic interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.